AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21763653
Drug: Genous™ endothelial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genous™ endothelial progenitor cell (EPC) capturing stent with statin therapy (HmG-CoA-reductase inhibitors)
Trial: 21763653
Drug: Genous™ endothelial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genous™ endothelial progenitor cell (EPC) capturing stent with statin therapy
Trial: 21765864
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (depression treatment referrals and print information on diabetes management)
Trial: 21767595
Drug: 15-μg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-μg dose of a monovalent, unadjuvanted inactivated 2009 H1N1 influenza vaccine
Trial: 21769849
Drug: Imatinib (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (up to 600 mg/day)
Trial: 21775510
Drug: Insulin-resistant women
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-resistant women (C-ISI <4.6)
Trial: 21775510
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (insulin-resistant and insulin-sensitive)
Trial: 21784508
Drug: AVI-4658 (phosphorodiamidate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVI-4658 (phosphorodiamidate morpholino oligomer) at doses of 0.5, 1.0, 2.0, 4.0, 10.0, and 20.0 mg/kg bodyweight
Trial: 21784781
Drug: Aztreonam for
RxNorm normalized name: Aztreonam for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam for inhalation solution (AZLI) thrice daily (AZLI3)
Trial: 21785475
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy continued during interventional techniques
Trial: 21785475
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy discontinued prior to interventional techniques
Trial: 21787417
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/day orally for 4 weeks on treatment, followed by 2 weeks off treatment
Trial: 21788422
Drug: ASO3-adjuvanted pandemic
RxNorm normalized name: pangamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASO3-adjuvanted pandemic (H1N1) 2009 vaccine (Arepanrix, GlaxoSmithKline Canada), 0.5-mL dose
Trial: 21789604
Drug: Self-collected swabs
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-collected swabs for high concentrations of A. vaginae (≥10^8 copies/mL)
Trial: 21789604
Drug: Self-collected swabs
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-collected swabs for high concentrations of G. vaginalis (≥10^9 copies/mL)
Trial: 21791058
Drug: Motesanib 100
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 100 mg QD + erlotinib (100 mg QD) + gemcitabine (1000 mg/m2)
Trial: 21791058
Drug: Motesanib 125
RxNorm normalized name: Motesanib
DrugBank: Motesanib (DB05575)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib 125 mg QD + erlotinib (150 mg QD)
Trial: 21791058
Drug: Motesanib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motesanib (50 mg QD, 75 mg BID, 125 mg QD, or 100 mg QD) + erlotinib (100 mg QD) + gemcitabine (1000 mg/m2)
Trial: 21791058
Drug: Erlotinib (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erlotinib (150 mg QD) + motesanib (100 or 125 mg QD)
Trial: 21791425
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of highly purified CD56(+)CD3(-) natural killer (NK) cells from haploidentical donors after fludarabine/cyclophosphamide immunosuppressive chemotherapy, followed by IL-2; median number of infused NK cells was 2.74 × 10(6)/Kg; T cells were < 10(5)/Kg.
Trial: 21791469
Drug: Bortezomib treatment
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib treatment
Trial: 21791473
Drug: Deferiprone 15
RxNorm normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Deferiprone 15 mg/kg bid
Trial: 21791475
Drug: Cytarabine 400
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine 400 mg/m(2)/day for 5 days + Tanespimycin 300 mg/m(2) on days 3 and 6
Trial: 21791513
Drug: Oral antiplatelet
RxNorm normalized name: simethicone
DrugBank: Simethicone (DB09512)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antiplatelet therapy (OAT) interruption for more than 5 days prior to surgery
Trial: 21791513
Drug: Preoperative haemoglobin
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative haemoglobin <10 g/dl
Trial: 21791513
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance <30 ml/min
Trial: 21791513
Drug: Creatinine clearance
RxNorm normalized name: Creatinine
DrugBank: Creatinine (DB11846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatinine clearance between 30 and 60 ml/min
Trial: 21791540
Drug: Plasma NGAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma NGAL and BNP combination
Trial: 21794112
Drug: Solutions implemented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solutions implemented in the study
Trial: 21794906
Drug: Food Allergy
RxNorm normalized name: Nutritional Supplement Oral Powder for Suspension [FOOD ALLERGY FORMULA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food Allergy Herbal Formula-2 (FAHF-2), 3.3 g (6 tablets) three times a day for 6 months
Trial: 21795476
Drug: ABT-888 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-888 (10 mg) administered orally twice a day (BID) with topotecan (0.6 mg/m²/d) on days one to five of 21-day cycles
Trial: 21795476
Drug: ABT-888 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-888 (10 mg) administered orally twice a day (BID) with topotecan
Trial: 21799479
Drug: Leptin levels
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leptin levels (ng/ml)
Trial: 21801604
Drug: Cervarix vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervarix vaccine (three doses in Months 0, 1, and 6)
Trial: 21802924
Drug: Hydro-alcoholic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydro-alcoholic extract of Lippia alba leaves, administered orally for 30-60 days.
Trial: 21807867
Drug: Copeptin <14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copeptin <14 pmol/L plus hscTnT <14 ng/L
Trial: 21812576
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) levels on admission
Trial: 21812736
Drug: Ambrisentan 5
RxNorm normalized name: ambrisentan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 5 mg once daily for 12 weeks
Trial: 21812736
Drug: Ambrisentan 10
RxNorm normalized name: ambrisentan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 10 mg once daily for an additional 12 weeks
Trial: 21812736
Drug: Ambrisentan 5
RxNorm normalized name: ambrisentan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 5 mg and 10 mg
Trial: 21812775
Drug: Sumavel DosePro
RxNorm normalized name: Sumavel DosePro
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sumavel DosePro (needle-free subcutaneous sumatriptan) 6 mg
Trial: 21812991
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavior therapy (ICBT) with therapist support for 15 weeks
Trial: 21812991
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavior therapy (ICBT) with therapist support
Trial: 21815133
Drug: Bevacizumab 10
RxNorm normalized name: bevacizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab 10 mg/kg on days 1 and 15 and topotecan 4 mg/m² on days 1, 8, and 15 of a 28-day cycle
Trial: 21815182
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of decitabine, arsenic trioxide, and ascorbic acid
Trial: 21815705
Drug: Atorvastatin lactone
RxNorm normalized name: citronellene lactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin lactone to atorvastatin acid ratio with a cut-off ratio set at 1.1
Trial: 21816031
Drug: RTS, S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS, S malaria candidate vaccine
Trial: 21816032
Drug: RTS,S/AS01 malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RTS,S/AS01 malaria candidate vaccine
Trial: 21818676
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT), 80 sessions
Trial: 21819507
Drug: Intravitreal EPO
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal EPO injection (1000 IU/0.05 mL)
Trial: 21821712
Drug: Cladribine 5.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine 5.6 mg/m² IV over 2 hours daily for 5 days followed by rituximab 375 mg/m² IV weekly for 8 weeks
Trial: 21823912
Drug: Aripiprazole (APZ)
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole (APZ) at flexible doses (maximum 15 mg/day) for up to 16 weeks
Trial: 21824458
Drug: Short half-life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short half-life antidepressants
Trial: 21824458
Drug: Antidepressant exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant exposure
Trial: 21824458
Drug: Overall antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall antidepressant exposure
Trial: 21826527
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m²) on Day 1, vinorelbine (27.5 mg/m²) on Days 8 and 15, filgrastim (5 µg/kg) on Days 2-21, and weekly trastuzumab (2 mg/kg after an initial bolus of 4 mg/kg)
Trial: 21828124
Drug: Blocking of
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocking of VLA-4 signaling in combination with cytarabine treatment
Trial: 21828141
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m², four weekly applications)
Trial: 21828142
Drug: Anti-PDGFRA antibodies
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-PDGFRA antibodies
Trial: 21831297
Drug: Transdermal rotigotine
RxNorm normalized name: rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal rotigotine patch (dosage ratio of 1.5:1)
Trial: 21831297
Drug: Oral ropinirole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ropinirole
Trial: 21831685
Drug: Voriconazole therapy
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole therapy
Trial: 21831954
Drug: Pazopanib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 600 mg QD
Trial: 21831954
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg QD
Trial: 21831954
Drug: Pazopanib (200-800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (200-800 mg)
Trial: 21835005
Drug: Age ≥
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age ≥ 51 years, prior neurologic damage, immunosuppression, combination of abnormal white blood cells (WBC) and elevated RDW
Trial: 21835005
Drug: Post chest
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post chest radiation state, prior neurologic damage, blood urea nitrogen (BUN) > 10.7 mmol/L, RDW > 14.5%
Trial: 21835825
Drug: ASA404 (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA404 (1800 mg/m²) plus docetaxel (75 mg/m²)
Trial: 21835825
Drug: ASA404 (1800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA404 (1800 mg/m²) plus docetaxel (60 mg/m²)
Trial: 21838412
Drug: Varenicline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (0.5 mg orally once daily for days 1 to 3; 0.5 mg twice daily for days 4 to 7; 1 mg twice daily for the remainder of a 12-week treatment period)
Trial: 21840522
Drug: Guidelines for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guidelines for analgesic treatment
Trial: 21841163
Drug: Clofarabine combined
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clofarabine combined with myeloablative doses of busulfan
Trial: 21846371
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d reduced viscosity barley β-glucan (BBG)
Trial: 21846371
Drug: 6 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/d reduced viscosity barley β-glucan (BBG)
Trial: 21846636
Drug: Inactivated influenza
RxNorm normalized name: influenza, inactivated, whole virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated influenza vaccine (TIV)
Trial: 21849481
Drug: Intervention therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention therapy for life-threatening symptoms (n = 29/38; 76%)
Trial: 21850464
Drug: Bortezomib and
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib and temozolomide (MTDs: 1.3 mg/m² for bortezomib and 200 mg/m² for temozolomide)
Trial: 21851846
Drug: Second generation
RxNorm normalized name: Second generation cephalosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Second generation antipsychotics (SGA) treatment
Trial: 21854593
Drug: Extended antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended antibiotic treatment with clindamycin and metronidazole plus vaginal gelatine capsules containing different strains of lactobacilli (109 freeze-dried bacteria per capsule)
Trial: 21855974
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Therapy-Endometrial (FACT-En)
Trial: 21857286
Drug: Didanosine, lamivudine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Didanosine, lamivudine, efavirenz (once-daily administration)
Trial: 21857490
Drug: Darunavir/ritonavir (DRV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir (DRV/r) 800/100 mg once daily and Raltegravir (RAL) 400 mg twice daily
Trial: 21859692
Drug: Canakinumab 150
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 150 mg or 2 mg/kg (≤40 kg) subcutaneously every 8 weeks for up to 2 years
Trial: 21859696
Drug: Adjuvant-free influenza
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant-free influenza A/California/7/2009 (pH1N1) vaccine
Trial: 21860633
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate 1-month depot administered intramuscularly every 28 days.
Trial: 21861537
Drug: Edoxaban 30
RxNorm normalized name: edoxaban 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 30 mg once-daily
Trial: 21861537
Drug: Edoxaban 60
RxNorm normalized name: edoxaban 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 60 mg once-daily
Trial: 21861537
Drug: Low-molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular weight heparin/warfarin
Trial: 26510020
Drug: Olaparib 400
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 400 mg twice a day
Trial: 21865346
Drug: Bosutinib 500
RxNorm normalized name: bosutinib 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bosutinib 500 mg once-daily dosing
Trial: 21867401
Drug: Oral tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tranexamic acid (TA) 1.3 g administered three-times daily for up to 5 days per menstrual cycle (maximum of 15 doses)
Trial: 21867539
Drug: Nurse-led, interprofessional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-led, interprofessional mental health promotion intervention (6-month program with regular home visits and monthly case conferences)
Trial: 21868014
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy with genetic variant analysis for COQ2 (rs4693570)
Trial: 21868014
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy with genetic variant analysis for ATP2B1 (rs17381194)
Trial: 21868014
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy with genetic variant analysis for DMPK (rs672348)
Trial: 21868572
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of donor T cells (2 × 10(8)/kg)
Trial: 21868778
Drug: Low glucose
RxNorm normalized name: ONE TOUCH LOW GLUCOSE CONTROL SOLN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low glucose suspend (LGS) feature of the Paradigm Veo insulin pump
Trial: 21869687
Drug: Vilazodone 40
RxNorm normalized name: vilazodone 40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilazodone 40 mg/d for 1 year
Trial: 21871057
Drug: Walnut oil
RxNorm normalized name: Walnut oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Walnut oil (0.5 mg/mL)
Trial: 21874317
Drug: Oral metronomic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metronomic cyclophosphamide (CTX) 65 mg/m² daily on days 1-14 plus capecitabine 1,000 mg/m² twice daily on days 1-14, repeated every 3 weeks until disease progression, unacceptable toxicity, or withdrawal of consent.
Trial: 21876119
Drug: Hydroxyurea therapy
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea therapy at maximum tolerated dose (MTD)
Trial: 21877169
Drug: Eculizumab, 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eculizumab, 600 mg every 2 weeks
Trial: 21877169
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange (initial treatment)
Trial: 21877508
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate spray 0.05% in the morning and calcitriol ointment 3 microg/g in the evening for up to 4 weeks
Trial: 21880803
Drug: 1-year lifestyle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-year lifestyle intervention (nutrition education, exercise training, behavior therapy)
Trial: 21884952
Drug: Strain-encoded magnetic
RxNorm normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strain-encoded magnetic resonance imaging (SENC) during high-dose dobutamine stress cardiac magnetic resonance imaging (DS-MRI)
Trial: 21887501
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate 1.4 mg/m2
Trial: 21887501
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate 0.7-2.0 mg/m2
Trial: 21888637
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (80 mg/m² IV on days 1 and 8) and capecitabine (900 mg/m² orally twice a day on days 1-14)
Trial: 21888637
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel and capecitabine
Trial: 21889330
Drug: Axitinib (5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axitinib (5mg twice daily)
Trial: 21890206
Drug: Intravenous N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous N-acetylcysteine (IV NAC)
Trial: 21890206
Drug: Oral N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral N-acetylcysteine (oral NAC)
Trial: 21892005
Drug: HPV-16/18 AS04-adjuvanted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV-16/18 AS04-adjuvanted vaccine (Cervarix®) administered in 3 doses at 0, 1, and 6 months
Trial: 21895032
Drug: Electrochemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrochemotherapy with intravenous bolus injection of bleomycin and electric pulses delivered via long needle electrodes
Trial: 21895536
Drug: Intra-arterial administration
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial administration of the oncolytic herpes virus NV1020
Trial: 21898376
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg once-daily
Trial: 21900113
Drug: RG7160 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RG7160 (50 to 1,400 mg) administered every week, every 2 weeks, or every 3 weeks
Trial: 21900189
Drug: Thalidomide-dexamethasone (TD)
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide-dexamethasone (TD) induction therapy and double autotransplantation (ASCT)